Business
Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation
Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics,
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform\n NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Phase 3 data for AXS-07 in the acute treatment of migraine has been selected as a featured presentation at the 2020 American Academy of Neurology (AAN) Science Highlights platform, to be held virtually September 23, 2020 at 12:15 PM Central Time. AXS-07 (MoSEIC™ meloxicam/rizatriptan) is Axsome’s novel, oral, multi-mechanistic investigational medicine for the acute treatment of migraine. The presentation will highlight new insights from the Phase 3 MOMENTUM trial of AXS-07, and will be followed with live Q&A. The AAN Science Committee reviewed over 150 late-breaking, or Emerging Science, abstracts and selected 12 to be featured presentations on the new 2020 AAN Science Highlights platform. The results of the Phase 3 MOMENTUM trial were one of the 12 selected abstracts. According to the AAN, the selected abstracts contain timely, significant, and innovative content. Details of the presentation are as follows: Title: Efficacy and Safety of AXS-07 for the Acute Treatment of Migraine: Results from the MOMENTUM (Maximizing Outcomes in Treating Acute Migraine) Phase 3 Randomized, Double-blind, Active- and Placebo-controlled StudySession: Emerging Science: Alzheimer's, Migraine, ALS and CIDPDate: Wednesday September 23, 2020Time: 12:15 – 12:30 PM Central TimeLocation: The 2020 AAN Science Highlights virtual platform will be available to everyone. Attendees will be asked to register to access the session at: https://www.aan.com/education-and-research/research/2020-aan-science-highlights/. A recording of the webinar will be available on the AAN Science Highlights platform following the session. A copy of the presentation will be available shortly after the meeting on Axsome’s website at www.axsome.com. About AXS-07 AXS-07 is a novel, oral, multi-mechanistic, investigational medicine under development for the acute treatment of migraine. AXS-07 consists of MoSEIC™ meloxicam and rizatriptan. Meloxicam is a new molecular entity for migraine enabled by Axsome’s MoSEIC (Molecular Solubility Enhanced Inclusion Complex) technology...